EFFECT OF ETRASIMOD ON CIRCULATING LYMPHOCYTES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Silvio Danese  1     Kiyomi Komori  2     Rathi D. Ryan  2     Fabio Cataldi  2     Caroline A. Lee  2     Martina Goetsch  3     Britta Siegmund  4    
1 IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, Italy
2 Arena Pharmaceuticals, a wholly-owned subsidiary of Pfizer Inc, New York, San Diego, United States
3 Arena Pharmaceuticals Development GmbH, a wholly-owned subsidiary of Pfizer Inc, New York, Zug, Switzerland
4 Charité - Universitätsmedizin Berlin, Berlin, Germany

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing